Introduction
============

Malignant pleural mesothelioma (MPM) is an uncommon type of malignancy with an aggressive nature. It is difficult to diagnose and its outcome is usually fatal, with a median survival of \<12 months, a number that has shown little change according to the Surveillance, Epidemiology, and End-Results (SEER) database \[[@b1-kjtcv-51-195]\]. MPM is known to show little response to chemotherapy and radiotherapy. Many studies have been conducted regarding the appropriate therapeutic modality for this disease, but its proper management is still a matter of debate. However, in patients with localized tumors without distant metastasis and the medical tolerance to undergo general anesthesia and surgery, complete surgical resection can be considered in order to achieve macroscopic cytoreduction, although the exact role of surgery has been a matter for debate \[[@b2-kjtcv-51-195]\].

The International Association for the Study of Lung Cancer currently defines the procedures for gross tumor reduction as extrapleural pneumonectomy (EPP), pleurectomy/decortication (P/D), and extended pleurectomy/decortication (e-P/D) \[[@b3-kjtcv-51-195]\]. EPP, which is the more aggressive, lung-sacrificing procedure, entails surgical removal of the ipsilateral lung, diaphragm, pleura, and the pericardium. In contrast, P/D spares the lung of the MPM-affected side, with removal of all gross tumors and pleura. The P/D procedure spares the pericardium and diaphragm, while the e-P/D procedure entails resection of the ipsilateral pericardium and diaphragm.

The Mesothelioma and Radical Surgery (MARS) trial in 2011 stated that EPP, in the context of trimodal therapy, was of no benefit and was harmful enough that further study was not warranted \[[@b4-kjtcv-51-195]\]. However, that study has been criticized for the factors it analyzed, its design, and the high rate of mortality following EPP, and to some, has been regarded as a study that can "lead research regarding MPM into a wrong direction" \[[@b5-kjtcv-51-195],[@b6-kjtcv-51-195]\]. To support this, most current studies in the literature support surgery as part of multimodal therapy \[[@b7-kjtcv-51-195]--[@b10-kjtcv-51-195]\]. In the SEER analysis of 13,734 MPM patients between 1973 and 2009, surgery was a predictive factor for longer survival \[[@b11-kjtcv-51-195]\].

In this context, we sought to analyze our single-institution experience with the surgical treatment of MPM by assessing patients' preoperative characteristics and their postoperative course, including complications, mortality, overall survival, and recurrence-free survival.

Methods
=======

This was a retrospective review of 21 patients who underwent surgical treatment for MPM at a single institution from January 2001 to June 2015. Patients' preoperative profiles and postoperative data were reviewed from medical records. Patients who presented with possible MPM were initially evaluated to obtain a histologic confirmation via thoracoscopic or needel biopsy. Staging following tissue confirmation was performed using computed tomography (CT), positron emission tomography scans to investigate possible metastasis, and magnetic resonance imaging. When the patient was deemed fit for surgical resection, preoperative echocardiography and a pulmonary function test including the diffusing capacity of the lungs for carbon monoxide were evaluated. Detailed demographics and preoperative data are shown in [Table 1](#t1-kjtcv-51-195){ref-type="table"}. The preoperative risk factors were classified according to the Charlson comorbidity index. The type of surgery was defined as EPP; pleurectomy if the whole parietal pleura, diaphragm, and pericardium were excised; and chest wall excision if only the affected portion of the chest wall was resected. The patient's final pathology and staging were classified postoperatively. Local recurrence was defined as metastasis in the ipsilateral hemithorax. All patients were staged as according to the seventh American Joint Committee on Cancer TNM staging system. The cohort's postoperative complications, mortality, overall survival, and recurrence rate were analyzed.

Results
=======

Patients' postoperative course, including complications, mortality, survival rate, and cause of death, is shown in [Table 2](#t2-kjtcv-51-195){ref-type="table"}. The most common histologic type was epithelioid (13 of 21, 61.8%), followed by sarcomatoid (2 of 21, 9.5%), biphasic (1 of 21, 4.8%), undifferentiated (1 of 21, 4.8%), and desmoplastic (1 of 21, 4.8%), and 5 cases were unclassified. The median hospital stay was 12 days (range, 1--63 days). The overall incidence of postoperative complications was 33.3%. Heart failure was the most common complication (n=3, 14.3%), followed by vocal cord palsy (n=2, 9.5%), pneumonia (n=1, 4.8%), and wound complications (n=1, 4.8%). In-hospital mortality occurred in 2 patients, one patient due to sudden cardiac arrest on postoperative day 0, owing to acute right ventricular failure, and the other due to postoperative bacterial pneumonia. Two patients died within 90 days after surgery: 1 due to aggravated heart failure, and 1 due to extensive systemic metastasis. The survival rate at 1 year, 3 years, and 5 years was 54.2%, 35.6%, and 21.3%, respectively, with a median survival duration of 14.3 months (range, 0--75.3 months) ([Fig. 1A](#f1-kjtcv-51-195){ref-type="fig"}). Overall, tumor recurrence was the most common cause of death (8 of 21), followed by heart failure (2 of 21) and severe acute renal failure, acute respiratory distress syndrome, pneumonia, and sepsis empyema, all with 1 occurrence each.

The median recurrence-free survival was 11.8 months in the total cohort, as shown in [Table 3](#t3-kjtcv-51-195){ref-type="table"}. The 1-year, 3-year, and 5-year recurrence-free survival rate was 41.8%, 33.4%, and 11.1%, retrospectively. In the 12 cases of recurrence, 8 patients showed local recurrence (defined as metastasis to the ipsilateral hemithorax) in the lung, rib, peritoneum, pleura, thoracic spine, and intrathoracic lymph node; 2 patients showed distant metastasis in the liver and retroperitoneum; and 2 patients showed both local and distant metastasis.

The patients who underwent pleurectomy showed the highest rate of survival at 43.6%, followed by the excision group at 34.9% and the EPP group at 17.5%, although this pattern was statistically non-significant (p=0.595) ([Fig. 2A](#f2-kjtcv-51-195){ref-type="fig"}). All but 3 patients (19 of 22) had a complete resection with negative resection margins, while the remaining 3 patients showed R1 resection and had a worse outcome ([Fig. 2B](#f2-kjtcv-51-195){ref-type="fig"}).

One patient of note is \#15 in [Table 4](#t4-kjtcv-51-195){ref-type="table"}. A 53-year old man without any other medical history other than diabetes mellitus was initially diagnosed with MPM. Neoadjuvant radiotherapy was done (60 Gy in 30 fractions) and the patient underwent pleurectomy with chest wall resection (8th--11th rib) and reconstruction, as well as wedge resection of the affected right lower lobe of the lung. All resection margins were negative for malignancy. However, 3 months later, a CT scan revealed an enlargement of the right costophrenic angle lymph node. He again underwent excision of the mass, which was consistent with metastasis of MPM. He then underwent 9 cycles of cisplatin and pemetrexed. After 7 years, he is still receiving outpatient follow-up without any symptoms or signs of recurrence.

Discussion
==========

Mesothelioma is a rare type of malignancy that is known for its aggressiveness, with a median survival of approximately 1 year. \[[@b1-kjtcv-51-195]\] The National Comprehensive Cancer Network (NCCN) 2017 clinical practice guidelines for MPM present general steps that clinicians must take when treating patients with MPM. Treatment options may include radiotherapy, chemotherapy, and surgery, and select patients (clinical stages I--III, resectable tumor, and medical tolerance to undergo therapy) are candidates for multimodal therapy \[[@b12-kjtcv-51-195]\].

However, the role of surgery itself has always been a matter for debate. A dataset study from 1990 to 2004 found that patients who underwent surgery showed a median overall survival of 11 months, as compared to 7 months in patients who did not undergo surgery (p\<0.0001) \[[@b13-kjtcv-51-195]\]. In this light, most of the current literature incorporates surgery as part of a multimodal therapeutic plan for MPM.

The surgical procedure can be either EPP, which is defined as en bloc resection of the pleura, lung, ipsilateral diaphragm, and often the pericardium, or P/D, which entails complete removal of the pleura, all gross tumor, and/or en bloc resection of the pericardium and/or diaphragm with reconstruction. Due to the lack of surgical margins and diffuse growth pattern, complete resection is microscopically impossible. Thus, the goal of any surgical procedure for MPM is complete gross cytoreduction of the tumor, or in other words, a macroscopic complete resection. Thus, when multiple site involvement is suspected, surgery should not be considered.

The 2017 NCCN guidelines suggest that both EPP and P/D are feasible surgical options, but which surgical method is oncologically better remains unknown. Two meta-analyses reported that P/D, when compared to EPP, was associated with a greater than 50% reduction in postoperative morbidity, a 2.5-fold lower short-term mortality rate, and an equivalent, if not greater, median overall survival \[[@b14-kjtcv-51-195],[@b15-kjtcv-51-195]\]. Support regarding P/D as the surgical method of choice over EPP is increasing, and the MARS-II trial comparing P/D to the best medical therapy is currently underway \[[@b16-kjtcv-51-195]\]. However, it must be pointed out that selection bias may play a part in the choice between EPP and P/D. As Flores et al. \[[@b17-kjtcv-51-195]\] pointed out in a 2008 study of 663 patients, many surgeons do not consider EPP and P/D to be exchangeable in terms of indications, and cases with bulky parenchymal involvement or involvement of the fissures may only be dealt with through EPP. It must also be pointed out that patients undergoing EPP have a higher tumor staging preoperatively than those undergoing P/D, which may affect postoperative mortality in terms of tumor recurrence. Moreover, patient comorbidities should also be considered, as those with a lower functional status or any other major underlying disease are probably unfit to undergo EPP. Clear guidelines regarding the surgical procedure of choice according to tumor staging and patient characteristics would be helpful for choosing the proper treatment.

In our series, except for patient \#1, all in-hospital mortality and morbidity occurred in patients who underwent EPP, which support the general consensus that EPP is associated with higher preoperative and postoperative mortality and morbidity. Our study could not provide sufficient data as to which operative method is associated with the most oncologic benefits due to the insufficient number of patients. However, patient \#15, as mentioned, underwent P/D as well as chest wall resection and another metastatectomy in the following years, and is still receiving follow-up with any sign of recurrence. This implies that P/D can also achieve complete resection of tumors, although the aggressiveness of MPM limits the percentages.

There is limited evidence regarding the best treatment option for cases of recurrent MPM, especially in terms of surgical intervention \[[@b18-kjtcv-51-195]\]. As shown by patient \#15, we consider surgery to be a feasible option in cases of recurrence of a single tumor in the ipsilateral chest cavity, which is a local recurrence that can be excised. We plan to do so in the future for further cytoreduction of MPM, although its efficacy must be demonstrated in a study with a larger group of cases of recurrent MPM.

A surgical lesson we recognized was that the inevitable sacrifice of the phrenic nerve must prompt the surgeon to preserve the integrity of the diaphragm, as elevation of the diaphragm and the underlying liver deterred a patient from undergoing postoperative adjuvant radiotherapy. We usually 'peeled' the outer layer of the diaphragm when preserving the diaphragm. However, the diaphragm lost integrity in terms of its function as time passed, and showed radiological signs of diaphragm elevation. Thus, when diaphragmatic involvement is suspected, total excision of the diaphragm and reconstruction with a non-native material may worth considering in light of possible future plans for radiotherapy and postoperative respiratory function.

In conclusion, although our data did not yield conclusive outcomes due to the small number of cases, we have illustrated the various forms of surgical management used in various cases of MPM. A further study is warranted with a larger patient cohort, which may lead to clear surgical guidelines regarding MPM.
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![(A) Overall survival of 21 patients. The overall median survival was 14.3 months. (B) Overall survival excluding 90-day mortality. The overall median survival was 29.0 months.](kjtcv-51-195f1){#f1-kjtcv-51-195}

![(A) Survival by operation type (p=0.595). (B) Survival by whether the resection was complete (p=0.826). EPP, extrapleural pneumonectomy.](kjtcv-51-195f2){#f2-kjtcv-51-195}

###### 

Demographic, perioperative, and survival data for the cohort (n=21)

  Characteristic                                                            Value
  ------------------------------------------------------------------------- ----------------
  Gender                                                                    
   Male                                                                     15
   Female                                                                   6
  Mean age (yr)                                                             55 (32--79)
  Smoking                                                                   16 (76.1)
  Exposure to asbestos                                                      6 (28.6)
  Mean forced expiratory volume in 1 second (L)                             70.4 (41--100)
  Mean diffusing capacity of the lungs for carbon monoxide (ml/min/mm Hg)   70.8 (42--116)
  Chief complaint                                                           
   Pleuritic pain                                                           8 (38.1)
   Dyspnea                                                                  7 (33.3)
   Cough                                                                    2 (19.1)
  Comorbidities (Charlson comorbidity index)                                
   Mean (range)                                                             1.29 (0--3)
   Median                                                                   1
  Side                                                                      
   Right                                                                    15 (71)
   Left                                                                     6 (29)
  Neoadjuvant treatment                                                     
   Chemotherapy                                                             1 (4.8)
   Radiotherapy                                                             1 (4.8)
  Types of surgical procedures                                              
   Extrapleural pneumonectomy                                               15 (71.4)
   Pleurectomy                                                              2 (9.5)
   Chest wall excision                                                      4 (19.1)
  Stage                                                                     
   II                                                                       5 (23.8)
   III                                                                      15 (71.4)
   IV                                                                       1 (4.8)
  Lymph node metastasis                                                     
   N0                                                                       12 (57.1)
   N1                                                                       2 (9.5)
   N2                                                                       5 (23.8)
   Nx                                                                       2 (9.5)
  Histologic type                                                           
   Epithelioid                                                              13 (61.9)
   Sarcomatoid                                                              2 (9.5)
   Biphasic                                                                 1 (4.8)
   Others[a)](#tfn2-kjtcv-51-195){ref-type="table-fn"}                      5 (23.8)
  Adjuvant therapy                                                          
   Chemotherapy                                                             5 (23.8)
   Radiotherapy                                                             7 (33.8)
   Chemotherapy and radiotherapy                                            1 (4.8)
   None                                                                     8 (42.9)

Values are presented as number, mean (range), or number (%).

Undifferentiated (n=1), desmoplastic (n=1), and unclassified (n=3).

###### 

Postoperative data for the cohort

  Variable                               Value
  -------------------------------------- ----------------
  Mean hospital stay (day)               16 (1--63)
  Median follow-up (mo)                  5.33 (0--75.3)
  Postoperative complication             7/21 (33.3)
  Heart failure                          3/21 (14.3)
  Pneumonia                              1/21 (4.8)
  Vocal cord palsy                       2/21 (9.5)
  Wound complication                     1/21 (4.8)
  In-hospital mortality                  2/21 (9.5)
  Cause of death                         
   Heart failure                         1/21 (4.8)
   Pneumonia                             1/21 (4.8)
   90-day mortality                      2/21 (9.5)
  Cause of death                         
   Heart failure                         1/21 (4.8)
   Recurrence                            1/21 (4.8)
  Survival rate (%)                      
   1 yr                                  54.2
   3 yr                                  35.6
   5 yr                                  21.3
  Median survival duration (mo)          14.3 (0--75.3)
  Cause of death                         
   Recurrence                            8 (42.9)
   Acute renal failure                   1 (4.8)
   Acute respiratory distress syndrome   1 (4.8)
   Heart failure                         2 (4.8)
   Pneumonia                             1 (4.8)
   Sepsis (empyema)                      1 (4.8)

Values are presented as mean (range), number (%), or %.

###### 

Recurrence-free survival

  Variable                                                              Value
  --------------------------------------------------------------------- ----------
  Recurrence pattern                                                    
  Local (ipsilateral mediastinal lymph node, chest wall)                8 (38.6)
  Distant (liver, bone, peritoneum)                                     2 (9.5)
  Mixed (local+distant)                                                 2 (9.5)
  Recurrence-free survival (%)                                          
   1 yr                                                                 41.8
   3 yr                                                                 33.4
   5 yr                                                                 11.1
  Median recurrence-free survival for different types of surgery (mo)   
   Extrapleural pneumonectomy                                           7.5
   Pleurectomy                                                          2.5
   Excision                                                             38.3
   Median recurrence-free survival                                      11.8

Values are presented as number (%), %, or median.

###### 

Individual profiles of the entire cohort

  No.   Age (yr)   Sex   Operation type                                       Side   Comorbidity (Charlson index)   Resection margin   Histology          Staging   Stage   Neoadjuvant therapy   Adjuvant therapy   Regimen                 Survival time (mo)   Recurrence site      Recurrence-free survival (mo)   Cause of death
  ----- ---------- ----- ---------------------------------------------------- ------ ------------------------------ ------------------ ------------------ --------- ------- --------------------- ------------------ ----------------------- -------------------- -------------------- ------------------------------- ----------------
  1     57         M     Lobectomy, RLL, partial resection of 8th--9th ribs   Rt.    1                              R0                 Undifferentiated   T3N0      3       \-                    \-                 \-                      1.8                  \-                   1.8                             Pneumonia
  2     49         M     EPP                                                  Rt.    0                              R0                 Sarcomatoid        T2N0      2       \-                    \-                 \-                      2.8                  \-                   26.8                            Heart failure
  3     47         M     EPP                                                  Rt.    0                              R0                 NA                 T2N0      2       CTx                   RTx                Cisplatin, pemetrexed   9                    Liver                29.0                            Recurrence
  4     45         F     EPP                                                  Rt.    0                              R0                 NA                 T3N0      3       \-                    CTx+RTx            Cisplatin, pemetrexed   10.9                 Chest wall, liver    2.8                             Recurrence
  5     59         M     EPP                                                  Lt.    1                              R0                 Epithelial         T2N0      2       \-                    RTx                \-                      39.7                 T12                  4.0                             Recurrence
  6     65         M     EPP                                                  Rt.    2                              R0                 Epithelial         T3N0      3       \-                    \-                 \-                      0.1                  \-                   1.9                             Heart failure
  7     57         M     EPP                                                  Rt.    0                              R0                 Epithelial         T3N2      3       \-                    RTx                \-                      4                    \-                   0.5                             ARDS
  8     57         M     EPP                                                  Rt.    3                              R0                 Epithelial         T3N2      3       \-                    CTx                Cisplatin, pemetrexed   20                   Retroperitoneal LN   75.3                            Recurrence
  9     52         M     EPP                                                  Lt.    1                              R0                 Epithelial         T2N2      3       \-                    CTx                Cisplatin, pemetrexed   7.7                  Liver, rib           3.0                             ARF
  10    61         F     EPP                                                  Lt.    2                              R1                 Epithelial         T2N1      3       \-                    RTx                \-                      9.2                  \-                   36.4                            Sepsis
  11    53         M     EPP                                                  Rt.    1                              R0                 Epithelial         T3N0      3       \-                    RTx                \-                      51.2                 RTx. rib             7.3                             Recurrence
  12    79         M     Chest wall resection                                 Rt.    3                              R0                 Epithelial         T3N1      3       \-                    \-                 \-                      14.3                 Lung                 5.7                             Recurrence
  13    63         M     EPP                                                  Lt.    2                              R0                 Desmoplastic       T2N0      2       \-                    CTx                Cisplatin, pemetrexed   2.3                  Chest wall           9.2                             Recurrence
  14    64         M     Pleurectomy                                          Rt.    2                              R1                 Biphasic           T3Nx      3       \-                    \-                 \-                      29                   Pleura               28.4                            Recurrence
  15    53         M     Pleurectomy with chest wall resection                Rt.    2                              R0                 Sarcomatoid        T4Nx      4       RTx                   \-                 \-                      66.7                 Cardiophrenic        LN                              2.7
  16    61         F     EPP                                                  Lt.    3                              R0                 NA                 T2N0      2       \-                    \-                                         75.3                                      7.9                             \-
  17    39         F     EPP                                                  Rt.    0                              R0                 Epithelial         T3N2      3       \-                    CTx                Cisplatin, pemetrexed   19                   Peritoneum           11.8                            \-
  18    60         M     EPP                                                  Rt.    2                              R0                 Epithelial         T3N0      3       \-                    \-                 \-                      62.5                 Chest wall           5.4                             \-
  19    32         F     EPP                                                  Rt.    0                              R0                 Epithelial         T2N2      3       \-                    CTx                Cisplatin, pemetrexed   3.8                  \-                   4.9                             \-
  20    50         M     Excision                                             Rt.    1                              R1                 Epithelial         T3N0      3       \-                    RTx                \-                      28.4                 \-                   3.8                             \-
  21    53         F     Chest wall resection                                 Lt.    1                              R0                 Epithelial         T3N0      3       \-                    RTx                \-                      4.9                  \-                   0.1                             \-

M, male; F, female; RLL, right lower lobe; Rt., right; Lt., left; EPP, extrapleural pneumonectomy; NA, unclassified; CTx, chemotherapy; RTx, radiotherapy; ARDS, acute respiratory distress syndrome; LN, lymph node; ARF, acute renal failure.
